Loading

CBD

  • by Paul Armentano, NORML Deputy Director July 10, 2017

    oil_bottlesThe US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … under medical supervision.”

    The agency has long contended that CBD, along with all organic cannabinoids, is — by default — a schedule I controlled substance because it is a naturally occurring component of the cannabis plant. (This position is similarly held by both the NIDA and the FDA.) Nonetheless, a growing body of science undermines the notion that CBD meets any of the criteria necessary for such classification.

    Specifically, clinical trial data finds that CBD is “safe,” “non-toxic,” and “well tolerated” in human volunteers. Even the director of the US National Institute on Drug Abuse acknowledges that CBD is “not mind-altering” and that it “appears to be a safe drug with no addictive effects.”

    Recently conducted controlled studies also acknowledge its therapeutic efficacy, particularly the ability of CBD dosing to mitigate treatment-resistant seizures, hypertension, and psychotic symptoms in humans. Other peer-reviewed data shows that CBD therapy holds promise for the treatment of “Parkinson’s disease, Alzheimer’s disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer.”

    That is why in addition to the thirty states that presently recognize medical cannabis, an additional 16 states also explicitly recognize the use of CBD as a viable medical treatment.

    Nonetheless, it remains unlikely that the DEA is going to amend its position any time soon. Further, police in recent months have begun initiating raids of CBD retailers, such as those reported here, here, and here. That is why it is critical that members of Congress move forward with legislation to remove the cannabis plant from the Controlled Substances Act.

    Presently, several pieces of federal legislation are pending to amend the federal classification of CBD as a schedule I substance. These include:

    HR 2020: Passage of this act would exclude CBD from the federal definition of ‘marihuana.’

    S. 1374/HR 2920: Passage of these Acts would exempt from federal prosecution those who are engaged in state-sanctioned medical cannabis activities; it would also remove CBD from the federal definition of ‘marihuana.’

    HR 2273/S. 1008: Passage of these Acts would exclude CBD and CBD-rich cannabis plants from the federal definition of ‘marihuana.’

    You can contact your members of Congress in support of these bills and other pending legislation by visiting NORML’s Take Action Center here.

  • by Paul Armentano, NORML Deputy Director July 5, 2017

    mj_researchThe prolonged daily administration of cannabinoids is associated with a reduction in migraine headache frequency, according to clinical trial data presented at the 3rd Congress of the European Academy of Neurology.

    Italian researchers compared the efficacy of oral cannabinoid treatments versus amitriptyline – an anti-depressant commonly prescribed for migraines – in 79 chronic migraine patients over a period of three months. Subjects treated daily with a 200mg dose of a combination of THC and CBD achieved a 40 percent reduction in migraine frequency – a result that was similar to the efficacy of amitriptyline therapy.

    Subjects also reported that cannabinoid therapy significantly reduced acute migraine pain, but only when taken at doses above 100mg. Oral cannabinoid treatment was less effective among patients suffering from cluster headaches.

    “We were able to demonstrate that cannabinoids are an alternative to established treatments in migraine prevention,” researchers concluded.

    Some five million Americans are estimated to experience at least one migraine attack per month, and the condition is the 19th leading cause of disability worldwide.

    According to retrospective data published last year in the journal Pharmacotherapy, medical cannabis consumption is often associated with a significant decrease in migraine frequency, and may even abort migraine onset in some patients.

    A just published review of several studies and case-reports specific to the use of cannabis and cannabinoids in the journal Cannabis and Cannabinoid Research concludes: “[I]t appears likely that cannabis will emerge as a potential treatment for some headache sufferers.”

    An abstract of the study, “Cannabinoids suitable for migraine prevention,” appears online here.

  • by Paul Armentano, NORML Deputy Director June 20, 2017

    oil_bottlesOral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.

    Investigators from the University of Nottingham in the United Kingdom assessed the effects of a single oral dose of 600 mg of CBD extract versus placebo in nine male subjects.

    Cannabidiol administration reduced resting systolic blood pressure and stroke volume (the amount of blood pumped by the left ventricle of the heart in one contraction). Compared to placebo, CBD intake was associated with reduced BP levels following exercise and in response to stress. Increased heart rate was observed following CBD administration, but no “adverse events” were reported by participants either during or following the study sessions.

    Authors concluded: “Our data show that a single dose of CBD reduces resting blood pressure and the blood pressure response to stress, particularly cold stress, and especially in the post-test periods. This may reflect the anxiolytic and analgesic effects of CBD, as well as any potential direct cardiovascular effects. … Further research is also required to establish whether CBD has any role in the treatment of cardiovascular disorders such as a hypertension.”

    Full text of the study, “A single dose of cannabisiol reduces blood pressure in healthy volunteers in a randomized crossover study,” is online here.

  • by Danielle Keane, NORML Associate July 15, 2016

    US_capitolMembers of Congress this week heard testimony on the state of marijuana research, and leading members of the U.S. Senate introduced legislation to potentially reclassify CBD. A medical marijuana initiative in Montana qualified for the November ballot and Governors in three states signed marijuana related bills into law. Keep reading below to get this week’s latest marijuana news and to find out how you can #TakeAction.

    Federal:
    On Wednesday, members of the U.S. Senate Judiciary Subcommittee on Crime and Terrorism, chaired by Senator Lindsey Graham (R-SC) held a hearing titled, “Researching Marijuana’s Potential Medical Benefits and Risks”. Testimony was provided by Senators Kirsten Gillibrand (D-NY) and Cory Booker (D-NJ), who are co-sponsors of the CARERS Act, as well as by officials from the National Institute on Drug Abuse (NIDA) and the Food and Drug Administration (FDA). While several witnesses were asked by the committee whether or not they expected the DEA to reschedule cannabis, none provided a direct answer. An archive of the hearing is available online here.

    Today, US Senators Charles Grassley (R-IA), Diane Feinstein (D-CA), Pat Leahy (D-VT), and Thom Tillis (R-NC) introduced legislation, the “Cannabidiol Research Expansion Act.” The Act requires the Attorney General to make a determination as to whether cannabidiol should be reclassified under the Controlled Substances Act and would expand research on the potential medical benefits of cannabidiol and other marijuana components. You can voice your support for this measure, as well as other pending federal legislation, by clicking here.

    State:

    Hawaii: On Tuesday, Governor David Ige signed legislation, House Bill 2707, to expand the state’s medical cannabis program.

    The measure expands the pool of practitioners who may legally recommend cannabis therapy to include advanced nurse practitioners. Separate provisions in the bill remove the prohibition on Sunday dispensary sales and on the possession of marijuana-related paraphernalia by qualified patients. Other language in the bill permits the transportation of medical marijuana across islands for the purposes of laboratory testing, but maintains existing prohibitions banning individual patients from engaging in inter-island travel with their medicine.

    Full text of the bill is available here.

    Missouri: Governor Jay Nixon signed legislation into law today making it easier for those with past marijuana convictions to have their records expunged.

    The legislative measure expands the number of offenses eligible for expungement from roughly a half dozen to more than 100 non-violent and non-sexual crimes. It also allows people to expunge their records sooner, shortening the waiting period to three years for misdemeanors and to seven years following a felony offense. However, the law does not take effect until January 1, 2018.

    Missouri’s NORML coordinator Dan Viets said, “This law will allow many thousands of people who have a marijuana conviction on their public records to escape the lifelong disabilities such a conviction has caused in the past.”

    For more information, contact Missouri NORML here.

    pills_v_potMontana: On Wednesday, a statewide initiative to expand and restore the state’s medical marijuana program qualified for the November ballot. The initiative is seeking to reverse several amendments to the program that were initially passed by lawmakers in 2011.

    If approved by voters, I-182 allows a single treating physician to certify medical marijuana for a patient diagnosed with chronic pain and includes post-traumatic stress disorder (PTSD) as a “debilitating medical condition” for which a physician may certify medical marijuana, among other changes. You can read the initiative language here.

    Pennsylvania: On Monday, legislation to establish “a pilot program to study the growth, cultivation or marketing of industrial hemp” was sent to Governor Wolf for his signature.

    This measures allows state-approved applicants to research and cultivate industrial hemp as part of an authorized pilot program. This proposal is compliant with Section 7606 of the omnibus federal farm bill, authorizing states to sponsor hemp cultivation pilot programs absent federal reclassification of the plant. More than two dozen states have enacted similar legislation permitting licensed hemp cultivation in a manner that is compliant with this statute. #TakeAction

    Rhode Island: Governor Gina Raimondo signed legislation, House Bill 7142, this week to make post-traumatic stress patients eligible for medical cannabis treatment and to accelerate access to those patients in hospice care. Members of both chambers previously overwhelmingly approved the measure. Full text of the bill is available here. The new law went into effect immediately upon the Governor’s signature.

  • by Danielle Keane, NORML Associate May 6, 2016

    US_capitolLegislation around the country is moving quickly and we’ve got numerous updates for you this week. Keep reading below to find out if your state is moving forward with marijuana law reform!

    Alabama: Governor Robert Bentley has signed legislation, House Bill 61, to protect qualified patients eligible for CBD therapy under a physician’s authorization from criminal prosecution. The measure, known as ‘Leni’s Law’, allows qualified patients to possess CBD preparations containing up to three percent THC. The new law takes effect June 1st, 2016.

    Colorado: House and Senate lawmakers have overwhelmingly approved legislation, House Bill 1373, to permit qualified patients access to the use formulations of medical cannabis while on school grounds.The measure now awaits action by Gov. John Hickenlooper, who indicated that he would sign the measure into law. “My son, if he needed medical marijuana and he needed it during the day while he was in school, I’d want him to have that opportunity,” Hickenlooper said.

    Connecticut: House and Senate lawmakers have approved legislation expanding patients’ access to the state’s medicinal cannabis program. House Bill 5450 permits qualifying patients under the age of 18 to possess and consume medical cannabis preparations and it also expands the list of qualifying illnesses eligible for cannabis therapy. Other provisions in the bill seek to establish a statewide clinical research program, and protect nurses from criminal, civil, or disciplinary sanction if they choose to administer marijuana to a qualifying patient in a hospital setting. The measure now awaits action by Governor Dannel Malloy. #TakeAction

    Hawaii: Legislation is pending before Governor David Ige to expand medical cannabis access and dispensing. The measure expands the pool of practitioners who may legally recommend cannabis therapy to include advanced nurse practitioners. Separate provisions in the bill remove the prohibition on Sunday dispensary sales and on the possession of marijuana-related paraphernalia by qualified patients.It also permits the transportation of medical marijuana across islands for the purposes of laboratory testing. #TakeAction

    Kansas: House and Senate lawmakers have signed off on sentencing reform legislation, House Bill 2049, that reduces criminal penalties for first-time marijuana possession offenses from a Class A misdemeanor (punishable by up to one year incarceration and a $2,500 fine) to a Class B misdemeanor (punishable by no more than six months in jail and a $1,000 fine). Second convictions will no longer be classified as a felony offense. The bill now heads to Gov. Brownback’s desk, and will become law if he does not veto it within 10 days. #TakeAction

    Louisiana: Senate legislation to fix and expand the state’s dormant medical marijuana law received a boost this week after a House Committee amended and passed the measure. Senate Bill 271 seeks to change the language of existing law so that physicians may ‘recommend’ rather than prescribe cannabis therapy. Under federal law, physicians cannot legally ‘prescribe’ cannabis or any schedule I substance. It also expands the pool of patients eligible to receive marijuana therapy. The legislation is scheduled to be heard by members of the House Health and Welfare Committee next week. #TakeAction
    marijuana_gavel
    New Hampshire: Members of the House Criminal Justice and Public Safety Committee voted 12 to 7 this week to amend Senate-backed sentencing reform legislation, Senate Bill 498, to also include provisions decriminalizing minor, first-time marijuana possession offenses. The amended language would make first-time offenses a civil violation rather than a criminal offense. The civil penalty would be limited to a fine only: no arrest, prosecution, or criminal record. Subsequent offenses would continue to be classified as misdemeanors. #TakeAction

    Oklahoma: House and Senate lawmakers have approved legislation, HB 2835, to expand the pool of patients eligible to possess cannabidiol under a physician’s authorization. As amended, House Bill 2835 would include legal protections to the following patient groups: those with “spasticity due to multiple sclerosis or due to paraplegia, intractable nausea and vomiting, appetite stimulation with chronic wasting diseases.” The measure also removes the age requirement limitation from existing law so that adults with various forms of epilepsy are eligible for CBD therapy. The measure now awaits action from Gov. Mary Fallin. #TakeAction

    Pennsylvania: Representative Ed Gainey is seeking co-sponsors for soon-to-be introduced legislation that would amend minor marijuana possession offenses to a non-criminal offense. Despite both local and nationwide progress on the issue of cannabis prohibition, Pennsylvania continues to charge over 18,000 individuals each year with minor possessory offenses. Please urge your House member to sign on as a co-sponsor to this important legislation. #TakeAction

    Rhode Island: Members of the Senate Judiciary Committee are scheduled to consider SB 2420, legislation to regulate the commercial production and retail sale of marijuana to those over the age of 21, on Tuesday, May 10th.  Adults would be permitted to purchase and possess up to one ounce of marijuana. It also permits adults to cultivate up to two marijuana plants (no more than 1 mature) at home for non-commercial purposes. You can read the full text of this proposal here. #TakeAction

    Tennessee: Two marijuana related measures became law recently in Tennessee. The first permits for the licensed cultivation of industrial hemp when “grown by an institution of higher education in this state that offers a baccalaureate or post-graduate level program of study in agricultural sciences.” The second, amends third-time marijuana possession offenses from a Class E felony, punishable by up to six years in prison, to a misdemeanor offense, punishable by no more than one year in jail. The new sentencing penalties take effect on July 1, 2016.

    For a summary of all pending marijuana legislation, be sure to check out our full #TakeAction center!

    And don’t forget to register to attend NORML’s 2016 Congressional Lobby Day  in Washington D.C. May 23rd and 24th! We have just recently confirmedthree members of Congress’ ability to address our group on Capitol Hill so you won’t want to miss it!

     

Page 1 of 812345...Last »